36701-89-0 Usage
Description
2-[3-(TRIFLUOROMETHYL)PHENOXY]NICOTINIC ACID, with the CAS number 36701-89-0, is a chemical compound characterized by its trifluoromethylphenoxy group attached to a nicotinic acid backbone. This structure endows the molecule with unique reactivity and properties, making it a valuable component in various chemical reactions and applications.
Uses
Used in Chemical Synthesis:
2-[3-(TRIFLUOROMETHYL)PHENOXY]NICOTINIC ACID is used as a reagent for the preparation of difluoroalkylarenes. Its application is particularly relevant in photocatalytic alkylation reactions involving trifluoromethylarenes and alkenes, which are important in the synthesis of various organic compounds and materials.
In the Chemical Industry:
2-[3-(TRIFLUOROMETHYL)PHENOXY]NICOTINIC ACID serves as a key intermediate in the production of complex organic molecules, especially those requiring the introduction of difluoroalkyl groups. Its use in this context is crucial for the development of new pharmaceuticals, agrochemicals, and advanced materials with improved properties.
In the Pharmaceutical Industry:
2-[3-(TRIFLUOROMETHYL)PHENOXY]NICOTINIC ACID may also find applications in the pharmaceutical industry, where it could be utilized in the design and synthesis of novel drug candidates. Its unique structure and reactivity could potentially lead to the development of new therapeutic agents with enhanced efficacy and selectivity.
In the Research and Development Sector:
2-[3-(TRIFLUOROMETHYL)PHENOXY]NICOTINIC ACID is used as a research tool to study the reactivity and properties of trifluoromethylarenes and their derivatives. This knowledge can be applied to develop new synthetic methods, improve existing processes, and explore the potential of these compounds in various applications.
Overall, 2-[3-(TRIFLUOROMETHYL)PHENOXY]NICOTINIC ACID is a versatile and valuable compound with a wide range of applications across different industries, particularly in chemical synthesis, pharmaceutical development, and research and development. Its unique structure and reactivity make it an essential component in the preparation of various organic compounds and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 36701-89-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,7,0 and 1 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 36701-89:
(7*3)+(6*6)+(5*7)+(4*0)+(3*1)+(2*8)+(1*9)=120
120 % 10 = 0
So 36701-89-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H8F3NO3/c14-13(15,16)8-3-1-4-9(7-8)20-11-10(12(18)19)5-2-6-17-11/h1-7H,(H,18,19)
36701-89-0Relevant articles and documents
Novel 2－ aryloxynicotinamide compound as well as preparation method and application thereof
-
, (2020/03/17)
The invention relates to a novel 2 - aryloxynicotinamide compound as well as a preparation method and application. of the 2 - aryloxynicotinamide compound as shown in the following formula (I). The compound can be used for preparing,aryloxy nicotinic acid compounds and derivatives thereof through a condensation reaction and a carbon hydrogen bond direct etherification method as shown in the formula shown in the specification. The invention relates to a novel method for preparing. 2 - aryloxynicotinic acid compounds and, derivatives thereof as shown in the structural formula shown. in the structural formula shown in the following formula. In Formula (I), the steric configuration of the carbon atom attached to the substituent R is R or S,Ar, and the aromatic substituent (is shown in more detail in the specification).
NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES
-
Page/Page column 22, (2010/05/13)
This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.
Nicotinamide Ethers: Novel Inhibitors of Calcium-Independent Phosphodiesterase and Rolipram Binding
Vinick, Fredric J.,Saccomano, Nicholas A.,Koe, B. Kenneth,Nielsen, Jann A.,Williams, Ian H.,et al.
, p. 86 - 89 (2007/10/02)
The synthesis and biological properties of a series of nicotinamide ethers are described.These compounds, structurally novel calcium-independent phosphodiesterase inhibitors, also inhibit the binding of rolipram to rat brain membranes and reverse rese
